Comparisons between rilpivirine (RPV) and integrase strand transfer inhibitors (INSTIs) in antiretroviral therapy (ART)-naïve HIV-infected individuals are currently lacking. Aim of the study was to compare, in an observational cohort setting, the durability of treatment of RPV- and INSTI-based first-line regimens.

Durability of rilpivirine- versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy

Luchino Chessa;
2021-01-01

Abstract

Comparisons between rilpivirine (RPV) and integrase strand transfer inhibitors (INSTIs) in antiretroviral therapy (ART)-naïve HIV-infected individuals are currently lacking. Aim of the study was to compare, in an observational cohort setting, the durability of treatment of RPV- and INSTI-based first-line regimens.
2021
Antiretroviral naïve; Dolutegravir; Elvitegravir; Raltegravir; Rilpivirine; Single tablet regimen
File in questo prodotto:
File Dimensione Formato  
IJAA 2021.pdf

Solo gestori archivio

Tipologia: versione post-print
Dimensione 600.21 kB
Formato Adobe PDF
600.21 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/317195
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact